Cristian Massacesi
Rueil-malmaison, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Implementation of digital health technology in clinical trials: the 6R framework.
Journal: Nature medicine
Published: August 16, 2023
Diversity of US participants in AstraZeneca-sponsored clinical trials.
Journal: Contemporary clinical trials
Published: August 04, 2023
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
Journal: Advances in therapy
Published: January 22, 2021
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 09, 2018
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Journal: Breast cancer research and treatment
Published: May 14, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: February 06, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: February 03, 2017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Journal: Lancet (London, England)
Published: December 16, 2016
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 03, 2016
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Journal: Anticancer research
Published: February 07, 2016
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Journal: OncoTargets and therapy
Published: January 22, 2016
Last Updated: 09/26/2026